CD274 and cervical cancer: Except for the two studies (IMMUVIX, GHR002) aimed at exploring the immune status of PD-1/PD-L1 in patients with locally advanced cervical cancer, the remaining 12 studies all looked into the applicability of PD-1/PD-L1 inhibitors in cervical cancer.